Profusa Announces 1-for-75 Reverse Stock Split
Rhea-AI Summary
Profusa (Nasdaq: PFSA) announced a 1-for-75 reverse stock split effective 12:01 am ET on February 9, 2026. Every 75 pre-split shares will consolidate into one post-split share, reducing outstanding shares from ~92.4 million to ~1.2 million.
The ticker remains PFSA and a new CUSIP 74319X207 will apply; fractional shares will be paid in cash. Authorized common shares remain 601 million.
Positive
- Outstanding shares reduced from ~92.4M to ~1.2M
- Ticker PFSA unchanged, reducing market confusion post-split
Negative
- Reverse split may reduce liquidity by consolidating share float
- Cash payments for fractional shares could create small transactional costs for shareholders
Market Reaction
Following this news, PFSA has declined 37.98%, reflecting a significant negative market reaction. Our momentum scanner has triggered 17 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.05. This price movement has removed approximately $3M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
PFSA’s -5.9% move occurred alongside declines in peers like AIMD -4.23% and ALUR -13.24%, suggesting sector pressure rather than an isolated move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Clinical results update | Positive | -3.4% | Positive US pilot study results for Lumee oxygen sensor at LINC 2026. |
| Jan 16 | Product launch | Positive | +4.1% | Launch of Lumee tissue oxygen Healthcare Research offerings for CRO market. |
| Jan 08 | Customer expansion | Positive | +0.1% | Addition of leading Greek vascular surgeon adopting Lumee Oxygen platform. |
| Dec 31 | Distribution deal | Positive | -14.0% | New French distributor MedSell and detailed European commercialization plans. |
| Dec 30 | Debt restructuring | Positive | +78.3% | Restructuring senior secured convertible notes to raise conversion floor and flexibility. |
Recent news has generally been positive, but price reactions have been mixed, with both strong rallies and notable sell-offs following constructive announcements.
This announcement follows a series of growth-focused updates. On Dec 30, 2025, Profusa restructured Senior Secured Convertible Notes to raise the conversion floor to $0.35, which preceded a 78.33% move. Late 2025 news emphasized European Lumee commercialization plans and multi-year revenue targets, though shares fell 13.96% after the Dec 31, 2025 update. Early 2026 brought commercial launches and positive clinical data, but price reactions remained inconsistent, framing the reverse split against persistent volatility and financing needs.
Market Pulse Summary
The stock is dropping -38.0% following this news. A negative reaction despite the mechanical nature of a reverse stock split fits a pattern of volatility seen around Profusa’s financing and strategic updates. Shares recently traded 96.41% below the 52-week high and below the $0.34 200-day MA, so sentiment was already fragile. Past positive announcements sometimes preceded declines, and today’s structural change could have amplified existing concerns about dilution history and capital needs rather than fundamentals.
Key Terms
reverse stock split financial
cusip financial
par value financial
AI-generated analysis. Not financial advice.
BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-seventy-five (1:75) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on February 9, 2026, and the Company’s common stock will open for trading on The Nasdaq Global Market on February 9, 2026 on a post-split basis, under the existing ticker symbol “PFSA” but with a new CUSIP number 74319X 207.
As a result of the reverse stock split, every seventy-five (75) shares of the Company’s common stock issued and outstanding prior to the opening of trading on February 9, 2026, will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of
As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced from approximately 92.4 million shares to approximately 1.2 million shares, and the number of authorized shares of common stock will remain at 601 million shares.
About Profusa
Based in Berkeley, California, Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Investor and Media Contacts:
email: info@coreir.com
phone: 1(212) 655-0924
FAQ
What does Profusa's 1-for-75 reverse stock split (PFSA) mean for shareholders?
When does the PFSA reverse stock split take effect and when will shares trade post-split?
Will Profusa (PFSA) issue fractional shares after the 1-for-75 reverse split?
How many authorized and outstanding shares will Profusa have after the reverse split?
Will Profusa's ticker or CUSIP change after the reverse stock split?
